LANGHORNE, Pa., April 07, 2025 (GLOBE NEWSWIRE) -- NEXGEL, Inc. (“NEXGEL” or the “Company”) (NASDAQ: “NXGL”), a leading provider of medical and over-the-counter (OTC) products including ultra-gentle, high-water-content hydrogels for healthcare and consumer applications, today announced that Adam Levy, Chief Executive Officer, will be presenting at the Planet MicroCap Showcase: Vegas 2025, taking place at the Paris Hotel & Casino, Las Vegas, NV on April 22-24, 2025. Planet MicroCap Showcase: Vegas 2025Presen ...

LANGHORNE, Pa., April 07, 2025 (GLOBE NEWSWIRE) -- NEXGEL, Inc. ("NEXGEL" or the "Company") (NASDAQ: "NXGL"), a leading provider of medical and over-the-counter (OTC) products including ultra-gentle, high-water-content hydrogels for healthcare and consumer applications, today announced that Adam Levy, Chief Executive Officer, will be presenting at the Planet MicroCap Showcase: Vegas 2025, taking place at the Paris Hotel & Casino, Las Vegas, NV on April 22-24, 2025. Planet MicroCap Showcase: Vegas 2025Presen ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON D.C. 20549 FORM 10-K (Mark One) ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended: December 31, 2024 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from ___________ to ___________ Commission file number: 001-41173 NexGel, Inc. (Exact name of registrant as specified in its charter) | Delaware | 26-4042544 | | --- | ...

Financial Data and Key Metrics Changes - For Q4 2024, revenue totaled $3.04 million, an increase of 181% compared to $1.08 million for Q4 2023 [26] - Full year 2024 revenue reached $8.69 million, up 112% from $4.09 million in 2023 [26] - Gross profit for Q4 2024 was $1.13 million, compared to $0.09 million for Q4 2023, with a gross profit margin of 37.2% [28] - Net loss for Q4 2024 was $0.85 million, an improvement from a net loss of $1.1 million in Q4 2023 [31] Business Line Data and Key Metrics Changes - The growth in revenue was primarily driven by branded consumer products and contract manufacturing [27] - Contract manufacturing saw increased demand from existing customers and new partnerships, notably with Cintas and Owens & Minor [12] - The consumer products segment expanded significantly, with brands like Medagel, Kenkoderm, and Silly George contributing to growth [18] Market Data and Key Metrics Changes - The partnership with Cintas is expected to enhance brand awareness and revenue growth for SilverSeal [14] - The company anticipates a healthy pipeline of potential new customers for 2025, indicating strong market demand [14] Company Strategy and Development Direction - The company aims to continue driving innovation and growth across key business segments, focusing on long-term shareholder value [24] - NEXGEL plans to expand its product offerings in 2025, including new products under the Medagel and Kenkoderm brands [18][19] - The company is strategically managing R&D exploration to ensure high ROI and alignment with its vision [23] Management's Comments on Operating Environment and Future Outlook - Management expressed optimism about achieving positive adjusted EBITDA in 2025, with expectations of continued revenue growth [37] - The company expects Q1 2025 revenue to be at least $2.75 million, with a target of at least $13 million for the full year [23] - Management highlighted the importance of partnerships and new product launches in driving future growth [24] Other Important Information - The company had a cash balance of approximately $1.81 million as of December 31, 2024 [33] - NEXGEL has 7,654,038 shares of common stock outstanding as of March 24, 2025 [33] Q&A Session Summary Question: Guidance on adjusted EBITDA and timeline to reach break-even - Management indicated that they expect to improve adjusted EBITDA in Q1 2025 and anticipate significant growth in Q2 as new customers come on board [37] Question: Details on the pipeline of new customers and industries - Management mentioned having four large opportunities progressing well, with varying timelines for onboarding and market entry [39] Question: Market opportunity for laser hair removal and promotional strategy - The company is partnering with Innovative Optics to leverage their relationships in the laser hair removal market, with plans to start selling products around mid-year 2025 [42][46] Question: Update on AbbVie Acoustic device launch - Management confirmed that they are on schedule to ship products to AbbVie in Q2 2025, with initial orders being received in Q1 [48]

Financial Performance - Revenue increased by 15% year-over-year, driven by strong sales in the Asia-Pacific region [1]. - Net profit margin improved to 12%, up from 10% in the previous quarter [2]. - Operating expenses rose by 8%, primarily due to increased marketing and R&D investments [3]. Market Expansion - The company successfully entered two new markets in Europe, contributing to a 20% increase in international sales [4]. - A new distribution center was opened in South America to support regional growth [1]. - Strategic partnerships were formed with local retailers in Southeast Asia to enhance market penetration [2]. Product Development - Launched three new products in the tech segment, which accounted for 25% of total revenue [3]. - R&D spending increased by 10% to accelerate innovation and product differentiation [4]. - Customer feedback on the latest product line has been overwhelmingly positive, with a 95% satisfaction rate [1]. Operational Efficiency - Implemented new supply chain management software, reducing logistics costs by 5% [2]. - Streamlined manufacturing processes, resulting in a 7% increase in production output [3]. - Employee training programs were expanded, leading to a 15% improvement in operational efficiency [4]. Strategic Initiatives - The company announced a new sustainability initiative aimed at reducing carbon emissions by 20% over the next five years [1]. - A share buyback program was initiated to return value to shareholders, with $500 million allocated for repurchases [2]. - Plans to invest $1 billion in digital transformation over the next three years were unveiled [3]. Risk Management - Identified potential risks in the supply chain due to geopolitical tensions and implemented contingency plans [4]. - Increased insurance coverage for key assets to mitigate potential financial losses [1]. - Conducted regular risk assessments to ensure compliance with evolving regulatory requirements [2].

Fourth quarter 2024 revenue totaled $3.04 million, an increase of 181%, as compared to $1.08 million for the same period the prior year Full year 2024 revenue totaled $8.69 million, an increase of 112%, as compared to $4.09 million in 2023 Over 100% full year and fourth quarter revenue growth year-over-year for third consecutive year Company issues revenue guidance of $13 million for 2025 and expects to achieve positive EBITDA during the year LANGHORNE, Pa., March 24, 2025 (GLOBE NEWSWIRE) -- NEXGEL, Inc. ( ...

Management will host a conference call at 4:30 p.m. ET on the same day LANGHORNE, Pa., March 19, 2025 (GLOBE NEWSWIRE) -- NEXGEL, Inc. (“NEXGEL” or the “Company”) (NASDAQ: “NXGL”), a leading provider of ultra-gentle, high-water-content hydrogel products for healthcare and consumer applications, today announced it will report its financial results for the fourth quarter and full year ended December 31, 2024, after the market closes on March 24, 2025. Following the release of its financial results, the Compan ...

Core Insights - NEXGEL, Inc. is set to present at the iAccess Alpha Virtual Best Ideas Spring Investment Conference on March 25-26, 2025, with CEO Adam Levy leading the presentation [1][2]. Company Overview - NEXGEL is a prominent provider of medical and over-the-counter (OTC) products, specializing in ultra-gentle, high-water-content hydrogels for healthcare and consumer applications [1][3]. - The company has over two decades of experience in developing and manufacturing electron-beam, cross-linked hydrogels [3]. - NEXGEL's product brands include SilverSeal®, Hexagels®, Turfguard®, Kenkoderm®, and Silly George® [3]. - The company maintains strategic contract manufacturing relationships with leading consumer healthcare companies [3].

Company Overview - NEXGEL, Inc. is a leading provider of healthcare, beauty, and over-the-counter (OTC) products, specializing in ultra-gentle, high-water-content hydrogels [3] - The company has been developing and manufacturing electron-beam, cross-linked hydrogels for over two decades [3] - NEXGEL's product brands include SilverSeal, Hexagels, Turfguard, Kenkoderm, and Silly George [3] - The company has established strategic contract manufacturing relationships with leading consumer healthcare companies [3] Upcoming Presentation - Adam Levy, the Chief Executive Officer of NEXGEL, will present at the Webull Consumer Virtual Webinar on February 18, 2025, at 2:40 p.m. ET [1][2] - A webcast of the presentation will be available at the provided link [2] - Investors can schedule one-on-one meetings with Mr. Levy through Webull or by contacting KCSA Strategic Communications [2]

Core Insights - NEXGEL, Inc. anticipates fourth quarter 2024 revenue of approximately $3.0 million, leading to a total revenue of about $8.6 million for the year, marking over 100% year-over-year growth for the third consecutive year [1][3] - The company projects at least $13 million in revenue for 2025 and aims to achieve positive cash flow from operations during that year [1][3] Business Segments - NEXGEL focuses on three core segments: contract manufacturing and white label, consumer products, and aspirational medical device development, which are expected to drive significant shareholder value [4] - The contract manufacturing and white label segment has been pivotal in growth, driven by increased demand from existing customers and onboarding of new global corporations [5] - Consumer products have seen remarkable expansion, particularly through the success of the Medagel brand and acquisitions of Kenkoderm and Silly George, with new product launches anticipated in 2025 [7][8] Customer and Product Developments - Two new large international customers have begun generating revenue, with one expected to contribute in the fourth quarter of 2024 and the other in the current quarter [6] - The partnership with Stada is progressing well, with the first product exceeding projections and two additional product launches expected in the second half of 2025 [9] Innovation and Future Opportunities - NEXGEL is exploring various applications for its high-water-content hydrogels, including a preclinical study using a hydrogel patch to deliver topical apremilast for treating stubborn lesions [10] - The company is optimistic about future opportunities and has a strong foundation for growth, with significant potential in its key business segments [11][12]